Mizolastine is an orally active, high-affinity, and specific peripheral histamine H1 receptor antagonist, classified as a second-generation antihistamine. It effectively inhibits the mRNA expression of VEGF165, VEGF120, TNF-α, and KC. Mizolastine is used in studies related to allergic rhinitis and chronic idiopathic urticaria.
- High-affinity and specific peripheral histamine H1 receptor antagonist
- Effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α, and KC
- Used in studies of allergic rhinitis and chronic idiopathic urticaria
- Inhibits VEGF, KC, and TNF-α release in mast cells
- Reduces VEGF165, VEGF120, TNF-α, and KC mRNA expression in mast cells
- Inhibits 5-LOX AA metabolite leukotriene B4 (LTB4) production
- Suppresses expression of 5-LOX, cytosolic PLA2 (cPLA2), 5-LOX-activating protein, and LTB4 receptor mRNA